	US 12,263,207 B2
	Human alpha-galactosidase variants
Nicholas J. Agard, San Francisco, CA (US); Mathew G. Miller, San Carlos, CA (US); Xiyun Zhang, Fremont, CA (US); and Gjalt W. Huisman, Redwood City, CA (US)
Assigned to Crosswalk Therapeutics, Inc., Cambridge, MA (US)
Filed by Crosswalk Therapeutics, Inc., Cambridge, MA (US)
Filed on Mar. 9, 2021, as Appl. No. 17/196,858.
Application 17/196,858 is a continuation of application No. 16/985,742, filed on Aug. 5, 2020, granted, now 10,973,888.
Application 16/985,742 is a continuation of application No. 15/529,383, abandoned, previously published as PCT/US2015/063329, filed on Dec. 2, 2015.
Claims priority of provisional application 62/216,452, filed on Sep. 10, 2015.
Claims priority of provisional application 62/095,313, filed on Dec. 22, 2014.
Prior Publication US 2021/0244804 A1, Aug. 12, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/70 (2006.01); A61K 9/00 (2006.01); A61K 38/01 (2006.01); A61K 38/47 (2006.01); C12N 9/24 (2006.01); C12N 9/40 (2006.01); C12N 15/80 (2006.01); C12N 15/85 (2006.01)

CPC A61K 38/47 (2013.01) [A61K 9/0019 (2013.01); C12N 9/2465 (2013.01); C12Y 302/01022 (2013.01)]

33 Claims

1. A recombinant alpha galactosidase A comprising an amino acid sequence comprising at least 90% sequence identity to SEQ ID NO: 5, wherein the amino acid sequence comprises at least a substitution at amino acid position 392, wherein the substitution at amino acid position 392 is 392G, 392P, 392S, 392T, 392A, 392D, 392Q, 392E, 392K, 392L, 392F, 392C, 392V, 392W, or 392N, and wherein the amino acid positions are relative to SEQ ID NO: 5.